A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors

Trial ID # NCT05194072
Phase I
Drug Class Antibody Drug Conjugates: B7H4
Drug Name Felmetatug vedotin
Alternate Drug Names SGN-B7H4V
Drugs in Trial Felmetatug vedotin
Eligible Participant

Advanced solid tumors

Patients Enrolled

86 patients in dose escalation; median 3 prior therapies (1-17), 21 OC


ORR: 20% (4PR, n=20)


Perez CA et al. First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001). Ann Oncol (2023) 34(2) abstract 660MO

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.